Costa Mesa, CA February 13, 2017 – Cerebain Biotech (OTCQB: CBBT) today announced that the company has engaged a Biotechnical Engineer to serve on the corporate team. The engagement comes as Cerebain readies itself for clinical trials and the FDA application process in conjunction with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia.
The Company has engaged the Biotechnical Engineer to support Sonos Models, Inc. as it continues the development of Cerebain’s Medical Device Product for the treatment of Alzheimer’s. The Biotechnical Engineer will assist across therapeutic areas throughout the product lifecycle from development to commercialization to post-launch and evaluate key aspects including industry trends, market evolution and growth opportunities.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
Forward Looking Statements
This news release contains certain “forward- looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.